Selumetinib, an Oral Anti-Neoplastic Drug, May Attenuate Cardiac Hypertrophy via Targeting the ERK Pathway

Chen Li; Zhongxiu Chen; Hao Yang; Fangbo Luo; Lihong Chen; Huawei Cai; Yajiao Li; Guiying You; Dan Long; Shengfu Li; Qiuping Zhang; Li Rao

doi:10.1371/journal.pone.0159079

Loading metrics

Open Access

Peer-reviewed

Research Article

Selumetinib, an Oral Anti-Neoplastic Drug, May Attenuate Cardiac Hypertrophy via Targeting the ERK Pathway

Chen Li ,

Contributed equally to this work with: Chen Li, Zhongxiu Chen

Affiliation Department of Cardiology, West China Hospital of Sichuan University, Chengdu, Sichuan, China
⨯
Zhongxiu Chen ,

Contributed equally to this work with: Chen Li, Zhongxiu Chen

Affiliation Department of Cardiology, West China Hospital of Sichuan University, Chengdu, Sichuan, China
⨯
Hao Yang,

Affiliation Department of Cardiology, West China Hospital of Sichuan University, Chengdu, Sichuan, China
⨯
Fangbo Luo,

Affiliation Department of Rehabilitation, Community Health Center of Shuangnan Wuhou District, Chengdu, Sichuan, China
⨯
Lihong Chen,

Affiliation Department of Biochemistry and Molecular Biology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, Sichuan, China
⨯
Huawei Cai,

Affiliation Department of Nuclear Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan, China
⨯
Yajiao Li,

Affiliation Department of Cardiology, West China Hospital of Sichuan University, Chengdu, Sichuan, China
⨯
Guiying You,

Affiliation Department of Cardiology, West China Hospital of Sichuan University, Chengdu, Sichuan, China
⨯
Dan Long,

Affiliation Key Laboratory of Transplant Engineering and Immunology, West China Hospital of Sichuan University, High-tech Zone, Chengdu, Sichuan, China
⨯
Shengfu Li,

Affiliation Key Laboratory of Transplant Engineering and Immunology, West China Hospital of Sichuan University, High-tech Zone, Chengdu, Sichuan, China
⨯
Qiuping Zhang,

Affiliation King’s College London British Heart Foundation Centre of Research Excellence, Cardiovascular Division, London, United Kingdom
⨯
Li Rao

* E-mail: lrlz1989@163.com

Affiliation Department of Cardiology, West China Hospital of Sichuan University, Chengdu, Sichuan, China
⨯

Selumetinib, an Oral Anti-Neoplastic Drug, May Attenuate Cardiac Hypertrophy via Targeting the ERK Pathway

Chen Li,
Zhongxiu Chen,
Hao Yang,
Fangbo Luo,
Lihong Chen,
Huawei Cai,
Yajiao Li,
Guiying You,
Dan Long,
Shengfu Li

Published: July 20, 2016
https://doi.org/10.1371/journal.pone.0159079

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Cardiac hypertrophy
Is the Subject Area "Cardiac hypertrophy" applicable to this article?

Thanks for your feedback.
ERK signaling cascade
Is the Subject Area "ERK signaling cascade" applicable to this article?

Thanks for your feedback.
Heart
Is the Subject Area "Heart" applicable to this article?

Thanks for your feedback.
Swimming
Is the Subject Area "Swimming" applicable to this article?

Thanks for your feedback.
Cardiomyocytes
Is the Subject Area "Cardiomyocytes" applicable to this article?

Thanks for your feedback.
Immunoblotting
Is the Subject Area "Immunoblotting" applicable to this article?

Thanks for your feedback.
Apoptosis
Is the Subject Area "Apoptosis" applicable to this article?

Thanks for your feedback.
Echocardiography
Is the Subject Area "Echocardiography" applicable to this article?

Thanks for your feedback.